180 related articles for article (PubMed ID: 15150587)
1. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer.
Hussain SA; Stocken DD; Peake DR; Glaholm JG; Zarkar A; Wallace DM; James ND
Br J Cancer; 2004 Jun; 90(11):2106-11. PubMed ID: 15150587
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of infiltrating cancer of the bladder with cisplatin, fluorouracil, and concurrent radiotherapy: results of a pilot study].
Chauvet B; Félix-Faure C; Davin JL; Berger C; Vincent P; Reboul F
Cancer Radiother; 1998 Apr; 2 Suppl 1():77s-81s. PubMed ID: 9749084
[TBL] [Abstract][Full Text] [Related]
3. A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer.
Hussain SA; Moffitt DD; Glaholm JG; Peake D; Wallace DM; James ND
Ann Oncol; 2001 Jul; 12(7):929-35. PubMed ID: 11521797
[TBL] [Abstract][Full Text] [Related]
4. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study.
Fellin G; Graffer U; Bolner A; Ambrosini G; Caffo O; Luciani L
Br J Urol; 1997 Jul; 80(1):44-9. PubMed ID: 9240179
[TBL] [Abstract][Full Text] [Related]
5. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
[TBL] [Abstract][Full Text] [Related]
6. Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer.
Chen WC; Liaw CC; Chuang CK; Chen MF; Chen CS; Lin PY; Chang PL; Chu SH; Wu CT; Hong JH
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):726-33. PubMed ID: 12788178
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
James ND; Hussain SA; Hall E; Jenkins P; Tremlett J; Rawlings C; Crundwell M; Sizer B; Sreenivasan T; Hendron C; Lewis R; Waters R; Huddart RA;
N Engl J Med; 2012 Apr; 366(16):1477-88. PubMed ID: 22512481
[TBL] [Abstract][Full Text] [Related]
9. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.
Mitin T; Hunt D; Shipley WU; Kaufman DS; Uzzo R; Wu CL; Buyyounouski MK; Sandler H; Zietman AL
Lancet Oncol; 2013 Aug; 14(9):863-72. PubMed ID: 23823157
[TBL] [Abstract][Full Text] [Related]
10. Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004).
Huddart RA; Hall E; Hussain SA; Jenkins P; Rawlings C; Tremlett J; Crundwell M; Adab FA; Sheehan D; Syndikus I; Hendron C; Lewis R; Waters R; James ND
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):261-9. PubMed ID: 23958147
[TBL] [Abstract][Full Text] [Related]
11. Rapidly alternating chemotherapy and radiotherapy instead of cystectomy for the treatment of muscle-invasive carcinoma of the urinary bladder: long term results of a pilot study.
Vikram B; Chadha M; Malamud SC; Hecht H; Grabstald H
Cancer; 1998 Mar; 82(5):918-22. PubMed ID: 9486582
[TBL] [Abstract][Full Text] [Related]
12. Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder.
Poortmans PM; Richaud P; Collette L; Ho Goey S; Pierart M; Van Der Hulst M; Bolla M;
Acta Oncol; 2008; 47(5):937-40. PubMed ID: 18568488
[TBL] [Abstract][Full Text] [Related]
13. Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution.
Peyromaure M; Slama J; Beuzeboc P; Ponvert D; Debré B; Zerbib M
Urology; 2004 Jan; 63(1):73-7. PubMed ID: 14751352
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial.
Huddart RA; Hall E; Lewis R; Porta N; Crundwell M; Jenkins PJ; Rawlings C; Tremlett J; Campani L; Hendron C; Hussain SA; James ND;
Eur Urol; 2020 Feb; 77(2):260-268. PubMed ID: 31843338
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.
Gogna NK; Matthews JH; Turner SL; Mameghan H; Duchesne GM; Spry N; Berry MP; Keller J; Tripcony L;
Radiother Oncol; 2006 Oct; 81(1):9-17. PubMed ID: 17011058
[TBL] [Abstract][Full Text] [Related]
16. [The efficacy and toxicity of gemcitabine and cisplatin chemotherapy in advanced/metastatic bladder urothelial carcinoma].
Gunlusoy B; Arslan M; Vardar E; Degirmenci T; Kara C; Ceylan Y; Kozacıoğlu Z
Actas Urol Esp; 2012 Oct; 36(9):515-20. PubMed ID: 22819345
[TBL] [Abstract][Full Text] [Related]
17. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
Hagan MP; Winter KA; Kaufman DS; Wajsman Z; Zietman AL; Heney NM; Toonkel LM; Jones CU; Roberts JD; Shipley WU
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):665-72. PubMed ID: 14529770
[TBL] [Abstract][Full Text] [Related]
18. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
Zietman AL; Shipley WU; Kaufman DS; Zehr EM; Heney NM; Althausen AF; McGovern FJ
J Urol; 1998 Nov; 160(5):1673-7. PubMed ID: 9783929
[TBL] [Abstract][Full Text] [Related]
20. A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil.
Anderson N; Lokich J; Moore C; Bern M; Coco F
Cancer Invest; 1999; 17(8):586-93. PubMed ID: 10592766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
